Inhibition of CHK1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells

Resistance to standard chemotherapy agents remains a major obstacle for improving treatment outcomes for acute myeloid leukemia (AML). The Bcl-2-selective inhibitor ABT-199 has demonstrated encouraging preclinical results, drug resistance remains a concern. Mcl-1 has been demonstrated to contribute...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncotarget
Auteurs principaux: Zhao, Jianyun, Niu, Xiaojia, Li, Xinyu, Edwards, Holly, Wang, Guan, Wang, Yue, Taub, Jeffrey W, Lin, Hai, Ge, Yubin
Format: Artigo
Langue:Inglês
Publié: Impact Journals LLC 2016
Sujets:
Research Paper
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5085189/
https://ncbi.nlm.nih.gov/pubmed/27166183
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.9185
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires